RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Drug discovery company SCYNEXIS, Inc., today announced that it has appointed infectious disease expert Carole Sable, MD, as Chief Medical Officer. Dr. Sable was most recently a Vice President at Merck & Co., Inc, initially as franchise integrator in Infectious Diseases and more recently as VP, Project Leadership and Management in Neurosciences and Ophthalmology.
"We look forward to her contributions as we continue to advance our lead candidate, SCY-078, a novel oral and intravenous antifungal compound, as well as our anti-viral platform."
"Carole brings to SCYNEXIS a significant tenure in the clinical development of infectious disease products, both as a clinician and in various corporate roles," said Dr. Yves Ribeill, SCYNEXIS president and chief executive officer. "We look forward to her contributions as we continue to advance our lead candidate, SCY-078, a novel oral and intravenous antifungal compound, as well as our anti-viral platform."
"SCY-078 represents a promising potential alternative for patients with invasive fungal infections who still experience significant morbidity and mortality despite antifungal treatment with currently available antifungal agents," commented Dr. Sable. "I am thrilled to be a part of SCYNEXIS' experienced and dedicated team as we look to bring novel anti-infectives to patients in need."
Prior to her recent involvement with Merck & Co., Dr. Sable served as Chief Medical Officer of Novexel SA and President of Novexel Inc., the US subsidiary, where she was responsible for clinical development and successfully filed two INDs and successfully completed Phase 2b studies for two antibacterial programs which led to the acquisition of Novexel SA by AstraZeneca. Previously, Dr. Sable was Executive Director of Infectious Disease and Vaccines Clinical Research at Merck & Co., Inc. where she was responsible for anti-bacterial, antifungal and vaccine development programs, including the clinical development of the antifungal agent Cancidas®. While with Merck, Dr. Sable also supervised the development and regulatory submissions for Invanz® and the in-licensing of the anti-infective amino-methylcycline PTK-0796 from Paratek Pharmaceuticals, as well as programs for sepsis, malaria, and anthrax. Dr. Sable began her career as an Assistant Professor of Medicine and Infectious Diseases at the University of Virginia in Charlottesville. She received an MD from Jefferson Medical College in 1983 and completed an internal medicine residency and infectious disease fellowship at the University of Virginia.
About SCYNEXIS
SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as a novel oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. In addition, we have clinical and preclinical programs based on the use of cyclophilin inhibitors to treat viral diseases, as well as contract research and development services in primarily in the field of animal health. www.scynexis.com
Contacts
SCYNEXIS
Amanda Mancuso, 919-544-8663
Chief of Staff
[email protected]
or
Media Relations
MacDougall Biomedical Communications
Cory Tromblee, 781-235-3060
[email protected]